At initial staging, one study showed that distant metastases or a secondary cancer was discovered in 22% of patients, which in turn led to adjustments in planned therapy [102]. The utility of FDG-PET in lower-stage cancer is more controversial. However, FDG-PET/CT does confer a high NPV of 87% for lymph node metastasis in N0 cancer and 99% for distant metastatic disease [37,49,85], which is valuable in directing therapy. FDG-PET/MRI Skull Base to Mid-Thigh FDG-PET/MRI is a new imaging modality with a growing body of evidence demonstrating the feasibility of use in routine clinical evaluation of head and neck tumors with FDG-PET/MRI shown to have similar results to FDG- PET/CT [42,52-54,56,57]. MRA Neck With IV Contrast There is no relevant literature to support the use of MRA neck with IV contrast in the initial staging of suspected or diagnosed cancer of the paranasal sinuses or nasal cavity. MRA Neck Without and With IV Contrast There is no relevant literature to support the use of MRA neck without and with IV contrast in the initial staging of suspected or diagnosed cancer of the paranasal sinuses or nasal cavity. MRA Neck Without IV Contrast There is no relevant literature to support the use of MRA neck without IV contrast in the initial staging of suspected or diagnosed cancer of the paranasal sinuses or nasal cavity. MRI Head With IV Contrast There is no relevant literature to support the use of MRI head with IV contrast in the initial staging of suspected or diagnosed cancer of the paranasal sinuses or nasal cavity. MRI Head Without and With IV Contrast There is no relevant literature to support the use of MRI head without and with IV contrast in the initial staging of suspected or diagnosed cancer of the paranasal sinuses or nasal cavity. The coverage of an MRI of the head and the sequences used may be insufficient to completely evaluate the primary site in the paranasal sinuses or nasal cavity and will not include regional nodal staging.
Staging and Post Therapy Assessment of Head and Neck Cancer. At initial staging, one study showed that distant metastases or a secondary cancer was discovered in 22% of patients, which in turn led to adjustments in planned therapy [102]. The utility of FDG-PET in lower-stage cancer is more controversial. However, FDG-PET/CT does confer a high NPV of 87% for lymph node metastasis in N0 cancer and 99% for distant metastatic disease [37,49,85], which is valuable in directing therapy. FDG-PET/MRI Skull Base to Mid-Thigh FDG-PET/MRI is a new imaging modality with a growing body of evidence demonstrating the feasibility of use in routine clinical evaluation of head and neck tumors with FDG-PET/MRI shown to have similar results to FDG- PET/CT [42,52-54,56,57]. MRA Neck With IV Contrast There is no relevant literature to support the use of MRA neck with IV contrast in the initial staging of suspected or diagnosed cancer of the paranasal sinuses or nasal cavity. MRA Neck Without and With IV Contrast There is no relevant literature to support the use of MRA neck without and with IV contrast in the initial staging of suspected or diagnosed cancer of the paranasal sinuses or nasal cavity. MRA Neck Without IV Contrast There is no relevant literature to support the use of MRA neck without IV contrast in the initial staging of suspected or diagnosed cancer of the paranasal sinuses or nasal cavity. MRI Head With IV Contrast There is no relevant literature to support the use of MRI head with IV contrast in the initial staging of suspected or diagnosed cancer of the paranasal sinuses or nasal cavity. MRI Head Without and With IV Contrast There is no relevant literature to support the use of MRI head without and with IV contrast in the initial staging of suspected or diagnosed cancer of the paranasal sinuses or nasal cavity. The coverage of an MRI of the head and the sequences used may be insufficient to completely evaluate the primary site in the paranasal sinuses or nasal cavity and will not include regional nodal staging.